The marketplace for drugs from the biotechnology industry, known as biologics, is damaged and needs repair. While biotechnology has revolutionized medical care and improved the lives of millions of patients, it is costly, with biologics running between $6,000 to $250,000 annually. With 400 biologics under development, the science has outpaced our ability to pay for it all.
Presently, however, there is no avenue for generic versions of biologic drugs to reach the market, which amounts to protectionism. This situation serves the biotech industry very well, but at the expense of all those who pay medical bills. Congress has an opportunity to knock down these barriers to more affordable medicine by passing the Access to Life-Saving Medicine Act. The effect of this bill would be similar to that of the 1984 Hatch-Waxman Act, when generic drug manufacturers were able to gain approvals for bioequivalent drugs from abbreviated new drug applications. The increased competition, in turn, spurred the pharmaceutical industry to develop new blockbuster drugs in the late 1980s and 1990s.
A similar scenario could occur in the biotech industry-and it could not come at a better time. Biologics are the fastest growing segment of the pharmaceutical marketplace. Most specialty drug dollars are concentrated in treating rheumatoid arthritis, multiple sclerosis, cancer, growth hormone deficiencies, anemia, anticoagulation therapy and hepatitis C. Spending for specialty drugs grew 16.1 percent in 2006, driven by a 7.3 percent increase in utilization and price inflation.
There is no denying their clinical benefit. Biologics keep patients alive and prevent prolonged hospital stays and surgeries, since they better target conditions and often are better tolerated than traditional medications. The Access to Life-Saving Medicine Act is a means for a more dynamic marketplace for this increasingly critical category of treatment.
Congress also needs to ensure that the full benefit of the bill reaches the marketplace. This can happen by increasing the budget for the FDA’s Office of Generic Drugs. Currently, 1,200 applications are backlogged at the office, which is responsible for approving safe and effective generic drugs. Giving the Office of Generic Drugs the tools to do its job could save the health care system billions, since every 1 percent increase in generic drug use saves the health care system $4 billion each year.
Higher funding for the Office of Generic Drugs, closing loopholes in the citizen petition process, and passage of the Access to Life-Saving Medicine Act are three important steps that need to happen in order to begin repairing the health care marketplace. As medicine becomes more personalized, patients and doctors need a greater selection of choices- including those that cost less-to meet patient needs.
David B. Snow Jr. is chairman and CEO of Medco Health Solutions, a pharmacy benefit manager.
Improvements in inflation data and belief in an upcoming rate cut are fueling CEO optimism.
Being authentic doesn't mean forgetting the weight of your words, and while you may want…
Capacity optimization is a new game these days, and other insights from the Chief Executive…
Your IT team should embrace artificial intelligence, argues Sacha Labourey, cofounder of CloudBees. Here’s how…
Here’s what organizations can do about it: Make sure there is continuous human involvement in…
Even the most successful CEOs can still be stymied by feelings of doubt. Here’s how…